Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptome modeling and phenotypic assays for cancer precision medicine.

Archives of pharmacal research - 1 Aug 2017

Jeong Euna, Moon Sung Ung, Song Mee, Yoon Sukjoon

Abstract excerpt

Cancer precision medicine requires clinically actionable biomarkers for patient stratification and a better prediction of clinical outcome. Although thousands of cancer-enriched mutated genes have been reported by global sequencing projects, to date, only a few oncogenic mutations have been confirmed as effective biomarkers in cancer therapies. The low frequency and varied profile (i.e., allele frequency,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Share to Transcriptome

Source

Identifiers

PMID: 28766239
DOI: 10.1007/s12272-017-0940-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptome modeling and phenotypic assays for cancer precision medicine.PMID 28766239Read ↗

Translating cancer genomes and transcriptomes for precision oncologySemantic proximity Read ↗

Functional genomics of cancer.Semantic proximity Read ↗

Multi-omics alleviates the limitations of panel-sequencing for cancer drug response predictionSemantic proximity Read ↗

The Pros and Cons of Incorporating Transcriptomics in the Age of Precision OncologySemantic proximity Read ↗

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy ResponseSemantic proximity Read ↗

A comprehensive transcriptional portrait of human cancer cell lines.Semantic proximity Read ↗

Transcriptome sequencing to detect gene fusions in cancerSemantic proximity Read ↗

Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.Semantic proximity Read ↗

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers.Semantic proximity Read ↗

Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study.Semantic proximity Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Harnessing AI to fuse phenotypic signatures for drug target identification: progress in computational modeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.